<DOC>
	<DOCNO>NCT01316237</DOCNO>
	<brief_summary>A Double-Blind , Randomized , Placebo-Controlled , Multiple Dose Ranging Study Evaluating Safety , Tolerability , Pharmacokinetics Antiviral Activity GS-6620 Treatment Naïve Subjects Chronic Hepatitis C Virus Infection .</brief_summary>
	<brief_title>A Study Evaluating Safety , Tolerability , Pharmacokinetics Antiviral Activity GS-6620 Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Adult subject ( 1860 year age 64 year age approval ) Documented chronic HCV infection least 6 month duration plasma HCV RNA ≥ 5 log10 IU/mL screening . HCV treatment naïve Estimated creatinine clearance ≥ 80 mL/min , QTcF interval ≤ 450 msec , QRS duration &lt; 100 msec , PR interval &lt; 220 msec , Body mass index ( BMI ) 19.0 34.0 kg/m2 , inclusive . Eligible subject must also HCV treatmentnaïve . Subjects prior documentation cirrhosis , excessive current alcohol intake , evidence hepatocellular carcinoma ( i.e. , αfetoprotein &gt; 50 ng/mL standard care measure ) Urine drug screen positive illicit/illegal drug ALT AST level &gt; 5 time upper limit normal range ( ULN ) Direct bilirubin &gt; ULN , clinical laboratory evidence hepatic decompensation ( i.e. , platelet &lt; 100,000/mm3 , prothrombin time ≥ 1.5 × ULN albumin &lt; 3.5 g/dL ) eligible study participation . Subjects absolute neutrophil count ( ANC ) &lt; 1,000 cells/mm3 ( &lt; 750 cells/mm3 black AfricanAmerican subject ) , hemoglobin ( Hb ) &lt; 11 g/dL , Coinfected hepatitis B virus ( HBV ) , human immunodeficiency virus ( HIV ) , another HCV genotype ( type 1 Cohorts 15 type 2 3 Cohort 6 ) eligible study participation . Evidence hepatocellular carcinoma Any sign decompensated liver disease , include prothrombin time ≥ 1.5 X ULN , platelets &lt; 100,000/mm3 albumin &lt; 3.5 g/dL screening OR current prior history clinical hepatic decompensation ( e.g. , ascites , jaundice , encephalopathy variceal hemorrhage ) History clinicallysignificant illness major medical disorder may interfere subject treatment , assessment compliance protocol History primary gastrointestinal disorder could interfere absorption study drug could interfere normal gastrointestinal anatomy motility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>GS-6620</keyword>
</DOC>